Mode
Text Size
Log in / Sign up
N/A Completed N=1,676 Randomized Other

Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer

Prostate Cancer · Cancer of the Prostate
Source: ClinicalTrials.gov NCT02079025 ↗
Enrolled (actual)
1,676
Serious AEs
0.4%
Results posted
Jan 2019
Primary outcomePrimary: Percentage of Participants With Clinically Significant Prostate Cancer — 36.6; 34.6; 36.6; 43.7 percentage of participants with csPCa

Summary

This trial uses a ultra high-resolution ultrasound system and specialized transducer, intended for use in prostate imaging. The system's image resolution is significantly better than the standard of care, due to its higher frequency. This allows the system to visualize suspicious areas and structures, and for greater accuracy for guided biopsy. The primary objective of this study is to demonstrate that ultra high-resolution transrectal ultrasound (UHR-TRUS) is superior to conventional low-resolution transrectal ultrasound (LR-TRUS) in detecting clinically significant cancer among men without known prostate cancer and with an indication for prostate biopsy. The secondary objective of this study is to compare the difference in the rate of detection of clinically significant cancer between LR-TRUS and UHR-TRUS, from before investigator training to after investigator training. The tertiary objective for the investigation is to compare the combined sensitivity and specificity in determining cancer detection overall for image-guided biopsy in UHR-TRUS vs. LR-TRUS.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Clinically Significant Prostate Cancer
36.6; 34.6; 36.6; 43.7 —
SECONDARY
Improvement of an Investigator's Ability to Detect Clinically Significant Cancer Using UHR-TRUS Post-training When Compared to Pre-training
32.4; 39.0 —
SECONDARY
Combined Sensitivity and Specificity in Determining Cancer Detection Overall for Image-guided Biopsy
38.0; 60.8; 89.5; 63.2 —

Eligibility Criteria

Inclusion Criteria

  • All men > 40 years age and 60cc
  • Men with anorectal abnormalities preventing TRUS-guided prostate biopsy
  • Men who are unable to provide their own informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02079025). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search